Mannosylated poly(acrylic acid)-coated mesoporous silica nanoparticles for anticancer therapy

Lee, Haesoo; Choi, Miseop; Kim, Ha Eun; Jin, Minki; Jeon, Woojin; Jung, Min-Cherl; Yoo, Hyelim; Won, Jong-Hee; Na, Young-Guk; Lee, Jae-Young; Seong, Hasoo; Lee, Hong-Ki; Cho, Cheong-Weon

doi:10.1016/j.jconrel.2022.06.064

Cited by 30 publications

(11 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MDA-MB-231 cells, a human breast cancer cell line, contain abundant mannose receptors on their cell surface. ,− This property has been widely exploited by designing NCs with mannosyl moieties to produce targeted drug delivery systems. ,, In our polymer structure, NCs were conferred with active targeting efficacy by conjugating mannose-associated monomers, which were predicted to bind strongly to MDA-MB-231 cells. We used FITC-labeled GOx to prepare BDOX-GOx FITC @NPs for examining the behavior of NCs toward cancer cells through fluorescence detection.…”

Section: Resultsmentioning

confidence: 99%

Synthesis of a Multifunctional Glyco-Block Copolymer through Reversible Addition–Fragmentation Chain Transfer Polymerization and Click Chemistry for Enzyme and Drug Loading into MDA-MB-231 Cells

Wu,

Lai,

Sivakumar

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Synthesis of a Multifunctional Glyco-Block Copolymer through Reversible Addition–Fragmentation Chain Transfer Polymerization and Click Chemistry for Enzyme and Drug Loading into MDA-MB-231 Cells

Wu,

Lai,

Sivakumar

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

“…These effects were reciprocated in reduced 21-day TV for both MAN–PAA-conjugated and unconjugated DOX–MSNPs, supported by the attenuated fluorescence signal until 21 days, with a higher effect for DOX-loaded NCs. These observations suggested a sustained therapeutic efficacy of MAN–PAA–DOX–MSNPs, with null residual accumulation in the heart, liver, spleen, lungs and kidneys [ 189 ]. This study, thereby, offers multiple insights, the foremost being the MAN coating.…”

Section: Discussion Of Recent Attempts Using Mesoporous Silica Nanopa...mentioning

confidence: 99%

Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment

et al. 2023

View full text Add to dashboard Cite

Breast cancer (BC) currently occupies the second rank in cancer-related global female deaths. Although consistent awareness and improved diagnosis have reduced mortality in recent years, late diagnosis and resistant response still limit the therapeutic efficacy of chemotherapeutic drugs (CDs), leading to relapse with consequent invasion and metastasis. Treatment with CDs is indeed well-versed but it is badly curtailed with accompanying side effects and inadequacies of site-specific drug delivery. As a result, drug carriers ensuring stealth delivery and sustained drug release with improved pharmacokinetics and biodistribution are urgently needed. Core–shell mesoporous silica nanoparticles (MSNPs) have recently been a cornerstone in this context, attributed to their high surface area, low density, robust functionalization, high drug loading capacity, size–shape-controlled functioning, and homogeneous shell architecture, enabling stealth drug delivery. Recent interest in using MSNPs as drug delivery vehicles has been due to their functionalization and size–shape-driven versatilities. With such insights, this article focuses on the preparation methods and drug delivery mechanisms of MSNPs, before discussing their emerging utility in BC treatment. The information compiled herein could consolidate the database for using inorganic nanoparticles (NPs) as BC drug delivery vehicles in terms of design, application and resolving post-therapy complications.

show abstract

“…Drug-loaded NCs can accumulate at a tumor site through the enhanced permeability and retention (EPR) effect . Further modification of NCs can be conducted using a targeting moiety to achieve active targeting. , The MDA-MB-231 cell line is a typical triple-negative breast cancer cell line that overexpresses the mannose receptor on the cell surface and mediates active endocytosis of glycoconjugates. ,, For instance, mannoside-modified glycosilica NPs, size ≈250 nm, were found be preferentially taken up by MDA-MB-231 cells, confirming the presence of mannose-dependent and clathrin-mediated endocytosis and phagocytosis in these cells . Stimulus-responsive drug delivery systems have attracted widespread attention because they have many favorable controlled release properties, such as low toxicity, biocompatibility, and biodegradability .…”

Section: Introductionmentioning

confidence: 88%

Mannoside-Functionalized Silica Nanocomposite-Encapsulated Doxorubicin for MDA-MB-231 Cancer Cell Targeting and Delivery

Lin

et al. 2023

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

The purpose of this study was to develop a carbohydrate silica nanocomposite, M-mDOX@SiO 2 , that can specifically target cancer cells and release the drug doxorubicin (DOX) specifically in an acidic tumor microenvironment (TME). First, DOX@SiO 2 was prepared using the Stober method to encapsulate DOX within silica nanoparticles (NPs). DOX@SiO 2 was then immersed in acidic PBS (pH 5) to obtain mesoporous silica-based NPs, termed mDOX@SiO 2 . Through mannoside and galactoside surface silane modification of mDOX@SiO 2 , we obtained M-mDOX@SiO 2 (specifically targeting the MDA-MB-231 cell surface receptor) and G-mDOX@SiO 2 (a nontargeting control), respectively. The synthesized silica NPs were characterized through ultraviolet−visible (UV−vis) spectrophotometry, fluorescence spectrometry, dynamic light scattering, and transmission electron microscopy. The anthrone−sulfuric acid method was used to measure the NP surface sugar content, and thermogravimetric analysis was applied to estimate the content of DOX loaded inside the NPs. The drug release profiles of M-mDOX@SiO 2 in different pH buffer solutions demonstrated that M-mDOX@SiO 2 can effectively release DOX in an environment with a pH of 5; moreover, the drug release rate increased as pH decreased. Fluorescence spectrometry and confocal microscopy were used to image MDA-MB-231 cells specifically targeted by M-mDOX@ SiO 2 . The MTT assay results revealed that M-mDOX@SiO 2 resulted in efficient cell growth inhibition. Finally, our animal experiments revealed that M-mDOX@SiO 2 demonstrated high antitumor efficacy. In conclusion, M-mDOX@SiO 2 has great potential as a drug delivery carrier.

show abstract

Mannosylated poly(acrylic acid)-coated mesoporous silica nanoparticles for anticancer therapy

Cited by 30 publications

References 53 publications

Synthesis of a Multifunctional Glyco-Block Copolymer through Reversible Addition–Fragmentation Chain Transfer Polymerization and Click Chemistry for Enzyme and Drug Loading into MDA-MB-231 Cells

Synthesis of a Multifunctional Glyco-Block Copolymer through Reversible Addition–Fragmentation Chain Transfer Polymerization and Click Chemistry for Enzyme and Drug Loading into MDA-MB-231 Cells

Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment

Mannoside-Functionalized Silica Nanocomposite-Encapsulated Doxorubicin for MDA-MB-231 Cancer Cell Targeting and Delivery

Contact Info

Product

Resources

About